What other stocks do shareholders of Telix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD) , Adverum Biotechnologies (ADVM) , Aimmune Therapeutics (AIMT) , ANI Pharmaceuticals (ANIP) , AxoGen (AXGN) , Biohaven (BHVN) , bluebird bio (BLUE) , Blueprint Medicines (BPMC) , Calithera Biosciences (CALA) and Codexis (CDXS) .

ASX:TLX

Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free TLX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 746,789 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Telix Pharmaceuticals alerts:

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About Telix Pharmaceuticals Stock (ASX:TLX)

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Ad American Alternative

Your Money is Not Safe

CLICK HERE TO GET YOUR GUIDE NOW

TLX Stock News Headlines

April 18, 2024 | fool.com.au

Why is the Telix share price jumping 15% to a record high?

April 17, 2024 | finanznachrichten.de

Telix Pharmaceuticals Limited: Q1 2024 Revenue and Business Update

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 17, 2024 | finance.yahoo.com

Q1 2024 Revenue and Business Update

April 16, 2024 | finance.yahoo.com

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER

April 15, 2024 | msn.com

'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stock

April 4, 2024 | msn.com

Why Aurelia Metals, Elders, GQG, and Telix shares are storming higher today

March 27, 2024 | finance.yahoo.com

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 12, 2024 | wsj.com

Telix Pharmaceuticals Ltd.

March 4, 2024 | finanznachrichten.de

Telix Pharmaceuticals Limited: Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

February 22, 2024 | msn.com

Inaugural profit overlooked as R&D spending soars at Telix Pharmaceuticals

February 22, 2024 | finance.yahoo.com

Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline

February 8, 2024 | finanznachrichten.de

QSAM Biosciences Inc.: QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals

February 7, 2024 | finance.yahoo.com

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

February 7, 2024 | finance.yahoo.com

QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals

February 2, 2024 | fool.com.au

2 top ASX growth shares to buy right now and hold for the long term

January 22, 2024 | finance.yahoo.com

Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)

January 4, 2024 | finance.yahoo.com

Telix Announces Planned Registered Public Offering and Listing in the United States

January 4, 2024 | finance.yahoo.com

UPDATE 2-Australia's Telix Pharmaceuticals jumps on potential US listing

January 4, 2024 | ca.finance.yahoo.com

Australia's Telix Pharmaceuticals jumps on potential US listing

January 3, 2024 | finance.yahoo.com

Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023 | finanznachrichten.de

Telix Pharmaceuticals Limited: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer

December 18, 2023 | finance.yahoo.com

Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer

December 4, 2023 | finance.yahoo.com

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

November 29, 2023 | finanznachrichten.de

Telix Pharmaceuticals Limited: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

November 29, 2023 | finance.yahoo.com

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS

See More Headlines

Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:TLX
CUSIP: N/A
CIK: N/A
Web: www.telixpharma.com
Phone: 61 4 4914 8448
Fax: N/A
Employees: 234
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A$0.02
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $5.21 million
Net Margins: 1.04%
Pretax Margin: N/A
Return on Equity: 4.55%
Return on Assets: 9.92%

Debt

Debt-to-Equity Ratio: 11.72
Current Ratio: 1.43
Quick Ratio: 3.00

Sales & Book Value

Annual Sales: $502.55 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 8.35
Book Value: A$0.46 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 323,990,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 2.35

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Christian P. Behrenbruch BEng(Hons) (Age 48)
DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Executive Director
Comp: $669.24k
Mr. Darren Smith B.Bus. (Age 59)
FCPA, M.B.A., Group Chief Financial Officer
Comp: $571.17k
Dr. Andreas Kluge M.D.
Ph.D., Chief Medical Advisor & Non-Executive Director
Mr. Richard Valeix M.B.A.
Group Chief Commercial Officer
Mr. Darren Patti
Group Chief Operating Officer
Dr. Michael Wheatcroft B.Sc.
BSc(Hons), Ph.D., Ph.D., (Cantab), Chief Scientist
Mr. Craig Ulrick
Chief Information Officer
Ms. Kyahn Williamson B.A.
Senior Vice President of Corporate Communications & Investor Relations
Ms. Melanie Farris (AGIA
ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & Compliance
Ms. Lena Moran-Adams L.L.B.
Group General Counsel

Key Competitors

View All Competitors

Insiders

TLX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Telix Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

This page (ASX:TLX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial